Evidence-based Treatment for Psoriasis Erythroderma_West China Medical Journal

Authors：

WEN Xiang , ZHOU Rongying , HAO Dan ,  JIANG Xian.

Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

JIANG Xian., Email: 419aaa@gmail.com

Keywords：

红皮病型银屑病; 循证治疗; 环孢素; 甲氨蝶呤

DOI：

10.7507/1002-0179.20130592

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　为红皮病型银屑病患者制定循证治疗方案。方法　 2012年3月收治1例红皮病型银屑病患者，充分评估患者情况后，提出临床问题，计算机检索Cochrane图书馆、 Medline、中文全文期刊医学数据库中相关研究，根据检索结果结合患者实际情况，制定治疗方案。结果　共检索到相关文献3篇。通过对检索结果进行分析，并结合患者意愿，为患者制定了采用甲氨喋呤的治疗方案。经过6个月的治疗随访，证实该方案适合该患者。结论　采用循证医学的方法，为红皮病型银屑病患者制定合理的治疗方案，可提高疗效。

Citation： WEN Xiang,ZHOU Rongying,HAO Dan,JIANG Xian.. Evidence-based Treatment for Psoriasis Erythroderma. West China Medical Journal, 2013, 28(12): 1877-1888. doi: 10.7507/1002-0179.20130592 Copy

1.	赵辩. 中国临床皮肤病学[M]. 南京: 江苏科学技术出版社, 2002: 867.
2.	邓丙戌. 银屑病[M]. 北京: 科学技术文献出版社, 2003: 701.
3.	李新宇. 抗银屑病药物研究的动向和未来[J]. 国外医学·皮肤性病学分册, 1997, 23(1): 17-21.
4.	孙建方. 脓疱型及红皮病型银屑病[J]. 国外医学·皮肤性病学分册, 1997, 23(1): 40-44.
5.	Flytström I, Stenberg B, Svensson A, et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial[J]. Br J Dermatol, 2008, 158(1): 116-121.
6.	沈军. 甲氨蝶呤与环孢素治疗银屑病的疗效对比分析[J]. 中国社区医师(医学专业半月刊), 2008, 10(24): 58.
7.	Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis[J]. N Engl J Med, 2003, 349(7): 658-665.
8.	邵长庚. 银屑病临床试验的设计和实际应用中的问题[J]. 临床皮肤科杂志, 2005, 34(2): 127-129.
9.	Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis[J]. J Am Acad Dermatol, 2005, 53(4): 652-659.
10.	Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis[J]. Clin Drug Investig, 2010, 30(2): 101-108.
11.	Baggott JE, Oster RA, Tamura T. Meta-analysis of cancer risk in folic acid supplementation trials[J]. Cancer Epidemiol, 2012, 36(1): 78-81.
12.	Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies[J]. Clin Dermatol, 2010, 28(1): 88-92.
13.	Atkinson K, Biggs J, Darveniza P, et al. Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation[J]. N Engl J Med, 1984, 310(8): 527.
14.	Melnikov S, Mayan H, Uchida S, et al. Cyclosporine metabolic side effects: association with the WNK4 system[J]. Eur J Clin Invest, 2011, 41(10): 1113-1120.
15.	Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure[J]. Cochrane Database Syst Rev, 2010, 20(1): CD007893.
16.	Dehesa L, Abuchar A, Nuno-Gonzalez A, et al. The use of cyclosporine in dermatology[J]. J Drug Dermatol, 2012, 11(8): 979.
17.	Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference[J]. J Am Acad Dermatol, 2010, 62(5): 838-853.

1. 　赵辩. 中国临床皮肤病学[M]. 南京: 江苏科学技术出版社, 2002: 867.
2. 　邓丙戌. 银屑病[M]. 北京: 科学技术文献出版社, 2003: 701.
3. 　李新宇. 抗银屑病药物研究的动向和未来[J]. 国外医学·皮肤性病学分册, 1997, 23(1): 17-21.
4. 　孙建方. 脓疱型及红皮病型银屑病[J]. 国外医学·皮肤性病学分册, 1997, 23(1): 40-44.
5. 　Flytström I, Stenberg B, Svensson A, et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial[J]. Br J Dermatol, 2008, 158(1): 116-121.
6. 　沈军. 甲氨蝶呤与环孢素治疗银屑病的疗效对比分析[J]. 中国社区医师(医学专业半月刊), 2008, 10(24): 58.
7. 　Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis[J]. N Engl J Med, 2003, 349(7): 658-665.
8. 　邵长庚. 银屑病临床试验的设计和实际应用中的问题[J]. 临床皮肤科杂志, 2005, 34(2): 127-129.
9. 　Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis[J]. J Am Acad Dermatol, 2005, 53(4): 652-659.
10. 　Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis[J]. Clin Drug Investig, 2010, 30(2): 101-108.
11. 　Baggott JE, Oster RA, Tamura T. Meta-analysis of cancer risk in folic acid supplementation trials[J]. Cancer Epidemiol, 2012, 36(1): 78-81.
12. 　Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies[J]. Clin Dermatol, 2010, 28(1): 88-92.
13. 　Atkinson K, Biggs J, Darveniza P, et al. Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation[J]. N Engl J Med, 1984, 310(8): 527.
14. 　Melnikov S, Mayan H, Uchida S, et al. Cyclosporine metabolic side effects: association with the WNK4 system[J]. Eur J Clin Invest, 2011, 41(10): 1113-1120.
15. 　Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure[J]. Cochrane Database Syst Rev, 2010, 20(1): CD007893.
16. 　Dehesa L, Abuchar A, Nuno-Gonzalez A, et al. The use of cyclosporine in dermatology[J]. J Drug Dermatol, 2012, 11(8): 979.
17. 　Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference[J]. J Am Acad Dermatol, 2010, 62(5): 838-853.

Previous Article
Evaluation of Diagnostic Criteria for Disseminated Intravascular Coagulation in Obstetric Patients
Next Article
The Research of the Relationship between Ambient Air Sulfur Dioxide and Allergen

West China Medical Journal

Evidence-based Treatment for Psoriasis Erythroderma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content